# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT CO M BINATIO N TEMPLATE

A. 510(k) Number: k112377

C. Measurand: Glucose, Sodium, Potassium, Chloride

D. Type of Test: Quantitative, Photometric and Ion Selective Electrode

E. Applicant: Shenzhen Mindray Bio-Medical Electronics Co., Ltd

F. Proprietary and Established Names: BS-400/CLC 720

# G. Regulatory Information:

1. Regulation section: 21CFR Sec.-862.1345 Glucose test system 21CFR Sec.-862.1665 Sodium test system 21CFR Sec.-862.1600 Potassium test system 21CFR Sec.-862.1170 Chloride test system 21CFR Sec.-862.2160-Discrete photometric chemistry analyzer for clinical use

2. Classification: Class II for assays Class I for analyzer (reviewed as part of Class II test systems)

3. Product code:

CFR - hexokinase, glucose   
JGS - electrode, ion specific, sodium   
CEM - electrode, ion specific, potassium   
CGZ - electrode, ion-specific, chloride   
JJE - analyzer, chemistry (photometric, discrete), for clinical use

4. Panel: Chemistry (75)

# H. Intended Use:

1. Intended use(s): See indications for use below

2. Indication(s) for use: The BS-400/CLC 720 Chemistry Analyzers are designed for clinical laboratory use, making direct quantitative measurements of $\mathrm { N a + }$ (sodium), $\mathrm { K } +$ (potassium), Cl- (chloride) in serum, plasma and urine samples and Glucose in serum samples plasma and urine samples. Additionally, other various chemistry assays may be adaptable to the analyzer depending on the reagent used to induce a photometric reaction.

Sodium measurements are used in the diagnosis and treatment diseases involving electrolyte imbalance.

Potassium measurements monitor electrolyte balance and in the diagnosis and treatment of diseases conditions characterized by low or high blood potassium levels.

Chloride measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders.

Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

3. Special conditions for use statement(s): Prescription use

4. Special instrument requirements: BS-400/CLC 720 Chemistry Analyzers

# I. Device Description:

The BS-400/CLC 720 are automated chemistry analyzers for in vitro diagnostic use in clinical laboratories and designed for in vitro quantitative determination of clinical chemistries in serum, plasma and urine samples. The device is composed of a photometric module and an Ion Selective Electrode module.

The Glucose reagent is ready to use and the composition is Liquid Glucose (Hexokinase) Reagent: Hexokinase (yeast) 2000U/L, G6PDH (Leuconostoc mesenteroides) 4000U/L, ATP 1.1 mmol/L, NAD $2 . 7 \mathrm { m m o l / L }$ , magnesium 2mmol/L, preservative and stabilizers. The reagent is manufactured by Carolina Liquid Chemistries for use on the BS-400/CLC 720 Chemistry Analyzers.

The ISE module is the same module as the one cleared on the BS- 200 analyzer and consists of ion selective electrodes for sodium, potassium, and chloride, a reference electrode and accessory reagents.

# J. Substantial Equivalence Information:

1. Predicate device name(s): BS-200 Chemistry Analyzer

2. Predicate 510(k) number(s): k072018

3. Comparison with predicate:

BS-400 and BS-200   

<table><tr><td colspan="1" rowspan="1">Feature</td><td colspan="1" rowspan="1">BS-400</td><td colspan="1" rowspan="1">BS-200</td></tr><tr><td colspan="1" rowspan="1">Indications</td><td colspan="1" rowspan="1">The BS-400/CLC 720 ChemistryAnalyzers are designed for clinicallaboratory use, making directquantitative measurements of Na+(sodium), K+ (potassium), Cl-(chloride) in serum, plasma and urinesamples and Glucose in serum samplesplasma and urine samples.Additionally, other various chemistryassays may be adaptable to the analyzerdepending on the reagent used toinduce a photometric reaction.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">System Function</td></tr><tr><td colspan="1" rowspan="1">System Control</td><td colspan="1" rowspan="1">Automatic, computer controlled</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">LIS externalconnectivitycapability</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Calibration/QC</td><td colspan="1" rowspan="1">Automatic and Manual calibration/QC</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Barcode</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="3" rowspan="1">Throughput (Max)</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">400 photometric tests per hour</td><td colspan="1" rowspan="1">200 photometrictests per hour</td></tr><tr><td colspan="3" rowspan="1">Configuration</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Analytical unit, Operational Unit</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="3" rowspan="1">Principle of Analysis</td></tr><tr><td colspan="1" rowspan="1">Mode of detection</td><td colspan="1" rowspan="1">Photometric</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Analytical methods</td><td colspan="1" rowspan="1">Endpoint Fixed-time Kinetic</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Calibration methods</td><td colspan="1" rowspan="1">Linear calibration and nonlinearcalibration</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="3" rowspan="1">Optical Measurement Unit</td></tr><tr><td colspan="1" rowspan="1">Measurement Modes</td><td colspan="1" rowspan="1">Absorbance</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Optical Modes</td><td colspan="1" rowspan="1">Monochromatic, Bichromatic</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Photometer</td><td colspan="1" rowspan="1">Multi-wavelengthdiffraction gratingspectrophotometer</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Wavelength</td><td colspan="1" rowspan="1">340nm, 380nm, 412nm, 450nm,505nm, 546nm, 570nm, 605nm,660nm, 700nm, 740nm and 800nm</td><td colspan="1" rowspan="1">340nm, 405nm,450nm,410nm,546nm, 578nm,630nm, 670nm</td></tr><tr><td colspan="1" rowspan="1">Linear absorbancerange</td><td colspan="1" rowspan="1">0-3.0 absorbance</td><td colspan="1" rowspan="1">0-4.0 absorbance</td></tr><tr><td colspan="1" rowspan="1">Light Source</td><td colspan="1" rowspan="1">Tungsten halogen lamp</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Detector</td><td colspan="1" rowspan="1">Photodiode</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="2" rowspan="1">Reaction Unit</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Reaction cuvettes</td><td colspan="1" rowspan="1">Plastic or Glass 90 non-disposable</td><td colspan="1" rowspan="1">Plastics, 80disposable</td></tr><tr><td colspan="1" rowspan="1">Reaction volume</td><td colspan="1" rowspan="1">150~360μL</td><td colspan="1" rowspan="1">180~500uL</td></tr><tr><td colspan="1" rowspan="1">Path length</td><td colspan="1" rowspan="1">5mm</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Reactiontemperature</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="3" rowspan="1">Sample and Reagent System</td></tr><tr><td colspan="1" rowspan="1">Sample disk</td><td colspan="1" rowspan="1">90 positions. 30 positions respectivelyfor inner, middle and outer circles.</td><td colspan="1" rowspan="1">40 sample tubepositions on theouter circle</td></tr><tr><td colspan="1" rowspan="1">Reagent disk</td><td colspan="1" rowspan="1">80 positions. 40 positions respectivelyfor inner and outer circles</td><td colspan="1" rowspan="1">40 reagent bottlepositions on theinner circle of thesample disk</td></tr><tr><td colspan="1" rowspan="1">Pipettor System</td><td colspan="1" rowspan="1">Positive displacement stepper motordriven</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Refrigeratortemperature</td><td colspan="1" rowspan="1">2-10</td><td colspan="1" rowspan="1">4-15°C</td></tr><tr><td colspan="1" rowspan="1">Sample Dispense</td><td colspan="1" rowspan="1">2μL -45μL</td><td colspan="1" rowspan="1">3μl -45μl</td></tr><tr><td colspan="1" rowspan="1">Reagent Dispense</td><td colspan="1" rowspan="1">20μL-350μL</td><td colspan="1" rowspan="1">30μ1-450μl</td></tr><tr><td colspan="1" rowspan="1">POWER</td><td colspan="2" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Input</td><td colspan="1" rowspan="1">110/115V~, 60Hz</td><td colspan="1" rowspan="1">100-130V ,50/60±1Hz</td></tr><tr><td colspan="3" rowspan="1">Operating environmental conditions</td></tr><tr><td colspan="1" rowspan="1">Temperature</td><td colspan="1" rowspan="1">15°C to 30°</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Humidity</td><td colspan="1" rowspan="1">35% to 80%, non-condensing</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">ISE (ion selective electrodetechnology)</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="3" rowspan="1">Sample Type</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Serum, plasma, or diluted urine</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="3" rowspan="1">Test</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Na+, K+, Cl</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="3" rowspan="1">Sample Size</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">70 μL Serum, plasma mode; 140 μLUrine mode</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="3" rowspan="1">ISE Calibration</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Two-point and single-pointcalibrations</td><td colspan="1" rowspan="1">same</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI - Evaluation of Precision Performance of Clinical Chemistry Devices - EP05-A2 CLSI - Evaluation of the Linearity of Quantitative Analytical Methods - EP06-A CLSI - Interference Testing in Clinical Chemistry - EP07-A2 CLSI - Method Comparison and Bias Estimation Using Patient Samples - EP09-A2 CLSI - Protocols for Determination of Limits of Detection and Limits of Quantitation - EP17-A

# L. Test Principle:

Glucose is phosphorylated with adenosine triphosphate (ATP) in the reaction catalyzed by hexokinase (HK). The product, glucose–6-phosphate (G6P) is then oxidized with the concomitant reduction of nicotinamide adenine dinucleotide (NAD) to NADH in the reaction catalyzed by glucose-6-phosphate-dehydrogenase (G6PDH). The formation of NADH causes an increase in absorbance at $3 4 0 \mathrm { n m }$ . The increase is directly proportional to the amount of glucose in the sample.

The ion selective electrodes develop a voltage that varies with the concentration of the ion $( \mathrm { N a } + , \mathrm { K } + , \mathrm { C l } - )$ to which they are specific. The relationship between the voltage developed and the concentration of the sensed ion is logarithmic and calculated by the Nernst equation.

# M. Performance Characteristics (if/when applicable):

These studies are intended to verify use of photometric and ISE technology on the analyzer.

Analytical performance:   
a. Precision/Reproducibility: Repeatability and within device imprecision for both serum/control and urine specimens are shown through the replicate assay of specimen pools and control materials over twenty days as described in CLSI document EP5-A2 Imprecision statistics are summarized below.

Imprecision of Glucose Measurements (in mg/dL)   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Within DeviceImprecision</td></tr><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Control pool 1</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>56.3</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>1.6%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Serum Pool</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>117.0</td><td rowspan=1 colspan=1>0.83</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>1.74</td><td rowspan=1 colspan=1>1.5%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Control pool 2</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>561.6</td><td rowspan=1 colspan=1>3.42</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>6.84</td><td rowspan=1 colspan=1>1.2%</td></tr><tr><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Urine pool 1</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>14.9</td><td rowspan=1 colspan=1>0.26</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>2.1%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Urine pool 2</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>194.3</td><td rowspan=1 colspan=1>1.08</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>1.91</td><td rowspan=1 colspan=1>1.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Urine pool 3</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>330.0</td><td rowspan=1 colspan=1>1.80</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>2.95</td><td rowspan=1 colspan=1>0.9%</td></tr></table>

ISE within-run precision   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=3>Level I</td><td rowspan=1 colspan=3>Level II</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Serum K+ (mmol/L)</td><td rowspan=1 colspan=1>3.49</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.54%</td><td rowspan=1 colspan=1>6.21</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.43%</td></tr><tr><td rowspan=1 colspan=1>Serum Na+ (mmol/L)</td><td rowspan=1 colspan=1>128.1</td><td rowspan=1 colspan=1>0.63</td><td rowspan=1 colspan=1>0.49%</td><td rowspan=1 colspan=1>150.8</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>0.33%</td></tr><tr><td rowspan=1 colspan=1>Serum Cl- (mmol/L)</td><td rowspan=1 colspan=1>84.8</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>1.12%</td><td rowspan=1 colspan=1>117.9</td><td rowspan=1 colspan=1>0.51</td><td rowspan=1 colspan=1>0.44%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>UrineLevel I</td><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=2>LevelI</td></tr><tr><td rowspan=1 colspan=1>Urine K+ (mmol/L)</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>0.51</td><td rowspan=1 colspan=1>2.48%</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00%</td></tr><tr><td rowspan=1 colspan=1>Urine Na+ (mmol/L)</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>1.60</td><td rowspan=1 colspan=1>2.46%</td><td rowspan=1 colspan=1>124</td><td rowspan=1 colspan=1>1.81</td><td rowspan=1 colspan=1>1.47%</td></tr><tr><td rowspan=1 colspan=1>Urine CL- (mmol/L)</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>1.08</td><td rowspan=1 colspan=1>2.03%</td><td rowspan=1 colspan=1>106</td><td rowspan=1 colspan=1>1.15</td><td rowspan=1 colspan=1>1.08%</td></tr></table>

ISE Total precision   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=3>Level I</td><td rowspan=1 colspan=3>Level II</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Serum K+ (mmol/L)</td><td rowspan=1 colspan=1>3.48</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.78</td><td rowspan=1 colspan=1>6.17</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.64</td></tr><tr><td rowspan=1 colspan=1>Serum Na+ (mmol/L)</td><td rowspan=1 colspan=1>129.1</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.78</td><td rowspan=1 colspan=1>150.4</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>0.59</td></tr><tr><td rowspan=1 colspan=1>SerumCl- (mmol/L)</td><td rowspan=1 colspan=1>85.1</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>1.29</td><td rowspan=1 colspan=1>117.1</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>0.82</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Urine Level I</td><td rowspan=1 colspan=3>UrineLevel II</td></tr><tr><td rowspan=1 colspan=1>Urine K+ (mmol/L)</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>2.23</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>0.56</td></tr><tr><td rowspan=1 colspan=1>Urine Na+ (mmol/L)</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>3.19</td><td rowspan=1 colspan=1>4.75</td><td rowspan=1 colspan=1>126</td><td rowspan=1 colspan=1>3.45</td><td rowspan=1 colspan=1>2.74</td></tr><tr><td rowspan=1 colspan=1>Urine CL- (mmol/L)</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>2.13</td><td rowspan=1 colspan=1>3.83</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>2.02</td><td rowspan=1 colspan=1>1.87</td></tr></table>

# b. Linearity/assay reportable range:

Linearity claims for both the serum and urine applications are validated using procedures based on CLSI document EP06-A

# Glucose

A first set of 0, 5, 25, 50, 100, 200, 300, 400, 500, 600 and $7 0 0 \mathrm { m g / d L }$ glucose (NIST SRM 917c) in a matrix of ${ 7 } \mathrm { g / d L }$ BSA, $0 . 8 5 \%$ sodium chloride, and an inert preservative for the serum/plasma application.

A second, analogous set of standards was similarly prepared in an aqueous matrix without BSA for the urine application.

# ISE

Linearity samples were prepared by using low and high samples with serial dilution schemes to cover 11 points in the test range.

<table><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Glucose mg/dLSerum/PlasmaBased on LOQ and Linearityy = 0.999x + 0.777R{2= 1</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>700</td></tr><tr><td rowspan=1 colspan=1>Glucose Urine mg/dLBased on LOQand Linearityy = 1.002x + 0.610 R2= 1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>700</td></tr><tr><td rowspan=1 colspan=1>ISE Based on Linearity andsupported by LOQ</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>K (mmol/L) serum(ISE)y = 1.0007x - 0.0051 R2 = 0.9998</td><td rowspan=1 colspan=1>0.94</td><td rowspan=1 colspan=1>8.2</td></tr><tr><td rowspan=1 colspan=1>Na (mmol/L) serum(ISE)y = 1.0001x - 0.0038 R2 = 0.9998</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>232.3</td></tr><tr><td rowspan=1 colspan=1>CL (mmol/L) serum(ISE)y = 1.0001x - 0.015 R2 = 0.9999</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>198</td></tr><tr><td rowspan=1 colspan=1>K (mmol/L) Urine(ISE)y = 0.9998x + 0.0203 R2 = 0.9987</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>209.3</td></tr><tr><td rowspan=1 colspan=1>Na (mmol/L) Urine(ISE)y = 1.0000x - 0.0024 R² = 0.9999</td><td rowspan=1 colspan=1>9.25</td><td rowspan=1 colspan=1>725.5</td></tr><tr><td rowspan=1 colspan=1>CL (mmol/L) Urine(ISE)y = 0.9999x + 0.0129 R2 = 0.9986</td><td rowspan=1 colspan=1>7.25</td><td rowspan=1 colspan=1>693.3</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods): Cleared under Point Multi-Analyte Chemistry Calibrator (k070207) Cleared under Medica EasyElectroLyte/RapidLyte $\mathrm { N a } / \mathrm { K } / \mathrm { C l }$ Analyzer (k000926)

# d. Detection limit:

The limits of blank (LoB) and detection (LoD) are listed below with the number of determinations they are based on. These limits were determined consistent with the guidelines of CLSI protocol EP17-A with proportions of false positives less than $5 \%$ and false negatives less than $5 \%$ .

Glucose   

<table><tr><td>Specimen</td><td>n LoB</td><td>LoD</td><td>LOQ</td></tr><tr><td>Serum</td><td>80 2.2</td><td>2.6</td><td>5.0 mg/dL</td></tr><tr><td>Urine</td><td>60 0.6</td><td>0.9</td><td>1.0 mg/dL</td></tr></table>

ISE   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>LoQ</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>K (mmol/L)</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>0.48</td></tr><tr><td rowspan=1 colspan=1>Na (mmol/L)</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>1.41</td><td rowspan=1 colspan=1>3.27</td></tr><tr><td rowspan=1 colspan=1>CL (mmol/L)</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.12</td><td rowspan=1 colspan=1>1.94</td><td rowspan=1 colspan=1>5.04</td></tr><tr><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>K (mmol/L)</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.50</td><td rowspan=1 colspan=1>1.76</td><td rowspan=1 colspan=1>3.01</td></tr><tr><td rowspan=1 colspan=1>Na (mmol/L)</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>3.50</td><td rowspan=1 colspan=1>6.88</td><td rowspan=1 colspan=1>11.22</td></tr><tr><td rowspan=1 colspan=1>CL (mmol/L)</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>2.96</td><td rowspan=1 colspan=1>5.55</td></tr></table>

# e. Analytical specificity:

Glucose

Effects of potentially interfering substances are shown by spiking serum pools with increasing amounts of interferent and measuring the effect of the additions on results. Bilirubin, hemoglobin, and Intralipid $^ \mathrm { \textregistered }$ $20 \%$ Emulsion are used to estimate icterus, hemolysis, and lipemia interference.

<table><tr><td>Interferent</td><td>Glucose Concentration</td><td>Interferent Concentration</td><td>Change in Glucose Result</td></tr><tr><td>Ascorbic acid</td><td>76 mg/dL 140 mg/dL</td><td>30 mg/L† 30 mg/L</td><td>-0.1 mg/dL* -0.8 mg/dL*</td></tr><tr><td rowspan="2">Bilirubin</td><td>78 mg/dL</td><td>4.8 mg/dL 8.0 mg/dL</td><td>-2.6 mg/dL -4.0 mg/dL</td></tr><tr><td>138 mg/dL</td><td>8.0 mg/dL 16.0 mg/dL</td><td>-3.3 mg/dL -6.9 mg/dL</td></tr><tr><td>Hemoglobin Triglycerides</td><td>74 mg/dL 134 mg/dL</td><td>400 mg/dL† 400 mg/dL</td><td>-2.0 mg/dL -3.8 mg/dL</td></tr><tr><td rowspan="2">(non-turbid)</td><td>69 mg/dL</td><td>728 mg/dL 910 mg/dL</td><td>+2.3 mg/dL +3.0 mg/dL</td></tr><tr><td>115 mg/dL</td><td>742 mg/dL 927 mg/dL</td><td>+2.2 mg/dL +2.7 mg/dL</td></tr><tr><td>Metronidazole</td><td>75 mg/dL 137 mg/dL</td><td>24 mg/L 48 mg/L 24 mg/L</td><td>+2.6 mg/dL +5.6 mg/dL +3.1 mg/dL</td></tr></table>

<table><tr><td>Tetracycline</td><td>76 mg/dL 140 mg/dL</td><td>15 mg/L† -1.5 mg/dL 15 mg/L -1.5 mg/dL</td></tr><tr><td>EDTA</td><td>76 mg/dL 145 mg/dL</td><td>8 mg/mL +0.2 mg/dL* 8 mg/mL 0.1 mg/dL*</td></tr><tr><td>Potassium oxalate</td><td>76 mg/dL 146 mg/dL</td><td>8 mg/dL +0.0 mg/dL* 8 mg/dL -0.8 mg/dL*</td></tr><tr><td>Sodium citrate</td><td>76 mg/dL 145 mg/dL</td><td>140 mg/dL† 1.1 1 mg/dL -2.8 mg/dL</td></tr><tr><td>Sodium fluoride</td><td>77 mg/dL</td><td>140 mg/dL 10 mg/dL +0.1 mg/dL*</td></tr><tr><td></td><td>145 mg/dL</td><td>+0.9 mg/dL*</td></tr><tr><td></td><td></td><td>10 mg/dL</td></tr></table>

\* Result is statistically insignificant at $\mathrm { p } { = } 0 . 0 5$ .   
$\dagger$ Highest level tested.

Serum pools containing $7 3 \mathrm { m g / d L }$ and $1 2 1 \mathrm { m g / d L }$ glucose and respectively spiked with $5 0 \mathrm { m g / d L }$ and $6 0 \mathrm { m g / d L }$ Intralipid $^ \mathrm { \textregistered }$ give lipemia index values of 47.1 and 54.9. Both pools appear moderately lipemic.

Visibly lipemic specimens with lipemic index values greater than 47 may produce elevated results. Assay these specimens using the Glucose (Blanked) Application.

ISE

Interference: Interference studies were performed based on CLSI document EP7-A2, the test results are showing below with no interference up to the amounts tested.

<table><tr><td rowspan=2 colspan=1>Item</td><td rowspan=1 colspan=3>Interference materials</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>LipemiaIntralipids®</td></tr><tr><td rowspan=1 colspan=1>K (mmol/L)</td><td rowspan=1 colspan=1>500 mg/dL</td><td rowspan=1 colspan=1>40 mg/dL</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Na (mmol/L)</td><td rowspan=1 colspan=1>500 mg/dL</td><td rowspan=1 colspan=1>40 mg/dL</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>CL (mmol/L)</td><td rowspan=1 colspan=1>500 mg/dL</td><td rowspan=1 colspan=1>40 mg/dL</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr></table>

Note: Hemolysis: Hemoglobin had no interference to serum $\mathrm { K } ^ { + }$ due to Hemoglobin used not having ${ \mathrm { K } } ^ { + }  \mathrm  $ , but Hemolysis will interfere with $\mathrm { K } ^ { + }$ due to the high $\mathrm { K } ^ { + }$ concentration in erythrocytes.

f. Assay cut-off: Not Applicable

2. Comparison studies:

a. Method comparison with predicate device: Method comparison using 110 serum and 108 plasma samples (vs. Beckman

Synchron CX7)   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>r2$</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>Range</td></tr><tr><td rowspan=1 colspan=1>GLU (mg/dL)</td><td rowspan=1 colspan=1>Serum + Plasma</td><td rowspan=1 colspan=1>218</td><td rowspan=1 colspan=1>0.999</td><td rowspan=1 colspan=1>0.989</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>38 - 672</td></tr><tr><td rowspan=1 colspan=1>GLU (mg/dL)</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>0.992</td><td rowspan=1 colspan=1>1.40</td><td rowspan=1 colspan=1>38 - 672</td></tr><tr><td rowspan=1 colspan=1>GLU (mg/dL)</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>0.999</td><td rowspan=1 colspan=1>0.986</td><td rowspan=1 colspan=1>1.22</td><td rowspan=1 colspan=1>42 - 672</td></tr></table>

Method comparison using urine samples (vs. Beckman Synchron CX7)

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>r^ 2$</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Slope Intercept</td><td rowspan=1 colspan=1>Range</td></tr><tr><td rowspan=1 colspan=1>GLU (mg/dL)</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>1.001</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>2- 660</td></tr></table>

ISE analysis (vs. BS-200 Chemistry Analyzer)   

<table><tr><td rowspan=1 colspan=1>Item(mmol/L)</td><td rowspan=1 colspan=1>RegressionSlope</td><td rowspan=1 colspan=1>RegressionIntercept</td><td rowspan=1 colspan=1>Correlationcoefficientsquare R2</td><td rowspan=1 colspan=1>AnalyzeRange of BS-400 (mmol/L)</td><td rowspan=1 colspan=1>Samplenumbers</td></tr><tr><td rowspan=1 colspan=1>Serum K+</td><td rowspan=1 colspan=1>1.0097</td><td rowspan=1 colspan=1>0.0591</td><td rowspan=1 colspan=1>0.997</td><td rowspan=1 colspan=1>0.93~8.18</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Serum Na+</td><td rowspan=1 colspan=1>1.0092</td><td rowspan=1 colspan=1>-0.7885</td><td rowspan=1 colspan=1>0.9975</td><td rowspan=1 colspan=1>70.7~232.3</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Serum Cl(mmol/L)</td><td rowspan=1 colspan=1>0.9763</td><td rowspan=1 colspan=1>1.3848</td><td rowspan=1 colspan=1>0.9946</td><td rowspan=1 colspan=1>49.5~198.0</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Urine K+</td><td rowspan=1 colspan=1>0.9718</td><td rowspan=1 colspan=1>1.7022</td><td rowspan=1 colspan=1>0.9996</td><td rowspan=1 colspan=1>4~210</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Urine Na+</td><td rowspan=1 colspan=1>1.0249</td><td rowspan=1 colspan=1>-13.487</td><td rowspan=1 colspan=1>0.9994</td><td rowspan=1 colspan=1>12~725</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Urine Cl</td><td rowspan=1 colspan=1>0.9984</td><td rowspan=1 colspan=1>2.1591</td><td rowspan=1 colspan=1>0.9996</td><td rowspan=1 colspan=1>7~690</td><td rowspan=1 colspan=1>40</td></tr></table>

$b$ . Matrix comparison:

See 2.a method comparison above for glucose plasma and urine and ISE urine claim. The plasma claim for the ISE electrodes was previously cleared under the Medica EasyElectroLyte/RapidLyte $\mathrm { N a } / \mathrm { K } / \mathrm { C l }$ Analyzer (k000926).

3. Clinical studies:

a. Clinical Sensitivity: Not Applicable   
$b$ . Clinical specificity: Not Applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not Applicable

4. Clinical cut-off: Not Applicable

5. Expected values/Reference range:

Glucose Sample Conventional Units SI Units

Serum/Plasma 74 to $1 0 0 \mathrm { m g / d L }$ 4.1 to 5.1 mmol/L Urine, Random 1 to $1 5 \mathrm { m g / d L }$ 0.1 to 0.8 mmol/L Urine, 24 hour < 0.5 g/day $< 2 . 8 7 \mathrm { m m o l / d a y }$

Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier Inc., St. Louis, MO, 2006.

Sodium – serum: 136-145 mmol/L, 24 hour urine: 40-220 mmol/L Potassium – serum: 3.5-5.1 mmol/L, 24 hour urine: 25-125 mmol/L Chloride – serum: 98-107 mmol/L, 24 hour urine: 110-250 mmol/L

Tietz, N.W., Clinical Guide to Laboratory Tests, Philadelphia, W.B. Saunders, 1990

# N. Instrument Name:

BS-400/CLC 720 Chemistry Analyzer

# O. System Descriptions:

1. Modes of Operation:

Random access instrument with ISE module

Does the applicant’s device contain the ability to transmit data to a computer, webserver, or mobile device?:

Yes __X__ or No

Does the applicant’s device transmit data to a computer, webserver, or mobile device using wireless transmission?:

Yes _ or No __X__

2. Software:

FDA has reviewed applicant’s Hazard Analysis and software development processes for this line of product types:

Yes ____X____ or No

3. Specimen Identification: Sample bar code option

4. Specimen Sampling and Handling:

Random access and stat mode operation Samples are loaded on sample disk

5. Calibration: Linear calibration and nonlinear calibration

6. Quality Control: Includes quality control program

P. O therSupportiveInstrum entPerform anceCharacteristicsDataNotCovered In The “Performance Characteristics” Section above: None

Q. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# R. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.